Cas:675602-96-7 4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine manufacturer & supplier

Chemical Name:4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine

CAS.NO:675602-96-7

Synonyms:4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine

Molecular Formula:C₁₅H₁₁N₃O₃S

Molecular Weight:313.33100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:122.20000

Exact Mass:313.05200

LogP:5.19720

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine Use and application,4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine technical grade,usp/ep/jp grade.

Related News: Therefore, the R & D capabilities and registration capabilities of API companies have become the core factors of competition. 4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine manufacturer Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access. 4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine supplier A number of UK citizens had trouble reaching the muster point in time for the first flight out because of road blocks and other restrictions in place in Wuhan. 4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine vendor In the process of fine chemical industry transfer, intermediates are a very important category, and they are also the main link for China to undertake transfers. 4-[4-(4-nitrophenoxy)phenyl]thiazol-2-ylamine factory Higher-risk MDS is a disease with significant unmet need, and we are pleased to be able to support healthcare professionals seeking access to rigosertib, ahead of its commercial launch,�� said Mark Corbett, EVP, Inceptua Medicines Access.